|
|
| | Benzenemethanamine, 4-[(trifluoromethyl)thio]-N-[[4-[(trifluoromethyl)thio]phenyl]methyl]- Basic information |
| | Benzenemethanamine, 4-[(trifluoromethyl)thio]-N-[[4-[(trifluoromethyl)thio]phenyl]methyl]- Chemical Properties |
| Boiling point | 325.0±42.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | pka | 7.26±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | Benzenemethanamine, 4-[(trifluoromethyl)thio]-N-[[4-[(trifluoromethyl)thio]phenyl]methyl]- Usage And Synthesis |
| Uses | MY33-3 is a potent and selective inhibitor of receptor protein tyrosine phosphatase (RPTP)β/ζ, with an IC50 of ~0.1 μM. MY33-3 also inhibits PTP-1B (IC50 ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction[1][2][3]. | | in vivo | MY33-3 (60 mg/kg; p.o. on days 3 and 4) reduces ethanol consumption when comparing day 2 with day 3. MY33-3 reduces preference for the ethanol solution on day 3[1].
MY33-3 (i.p.) reverses the Sevoflurane-induced decrease in the discrimination index and impaired motor learning ability[3]. | Animal Model: | Male C57BL/6J mice (8-10 weeks of age) are received two-bottle drinking in the dark (DID) procedure using 20% ethanol[1] | | Dosage: | 60 mg/kg | | Administration: | P.o. 1 hour before the drinking session in the DID test on days 3 and 4 | | Result: | Reduced ethanol consumption when comparing day 2 with day 3.
Showed a reduced preference for the ethanol solution.
Not affected total fluid consumption.
|
| | References | [1] Fernández-Calle R, et, al. Pharmacological inhibition of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) modulates behavioral responses to ethanol. Neuropharmacology. 2018 Jul 15;137:86-95. DOI:10.1016/j.neuropharm.2018.04.027
[2] Fernández-Calle R, et, al. Role of RPTPβ/ζ in neuroinflammation and microglia-neuron communication. Sci Rep. 2020 Nov 20;10(1):20259. DOI:10.1038/s41598-020-76415-5
[3] Mao S, et, al. Pleiotrophin Potentiates Sevoflurane Anesthesia-induced Learning Deficits in Mice. J Mol Neurosci. 2022 Jan;72(1):48-55. DOI:10.1007/s12031-021-01885-9 |
| | Benzenemethanamine, 4-[(trifluoromethyl)thio]-N-[[4-[(trifluoromethyl)thio]phenyl]methyl]- Preparation Products And Raw materials |
|